Leadership & Pay ·
TScan Therapeutics announced a strategic reorganization to prioritize its in vivo solid tumor program, advancing two…
TCRXTScan Therapeutics, Inc.
TScan Therapeutics announced a strategic reorganization to prioritize its in vivo solid tumor program, advancing two product candidates targeting PRAME and MAGE-A4 into IND-enabling studies with plans for Phase 1 initiation by Q4 2027. The company paused further enrollment in the Phase 3 ALLOHA-2 study of TSC-101 due to capital constraints, though it will continue monitoring enrolled patients while seeking partnerships. Concurrently, TScan implemented a workforce reduction of approximately 75%, expecting $4.1 million in employee-related costs and cumulative savings of $55.0 million through the end of 2027. CFO Jason A. Amello and CMO Chrystal Louis were terminated without cause, with CEO Gavin MacBeath assuming principal financial officer duties. Additionally, TScan received a Nasdaq notice for failing to meet the $1.00 minimum bid price rule, granting an 180-day compliance period until February 23, 2027. TScan Therapeutics is a clinical-stage biotechnology company developing T cell receptor (TCR)-engineered T cell therapies for cancer.